Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Other Accumulated Expenses data on file, last reported at $83.0 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $83.0 million, up 1647.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $83.0 million (up 1647.37% YoY), and the FY2025 annual result was $38.2 million, changed N/A from the prior year.
• Other Accumulated Expenses climbed to $83.0 million in Q1 2026 per SUPN's latest filing, from $38.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $83.0 million in Q1 2026 and troughed at $710000.0 in Q3 2023.
• A 5-year average of $17.7 million and a median of $8.4 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses plunged 91.33% in 2023, then soared 1647.37% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $16.9 million in 2022, then plunged by 74.6% to $4.3 million in 2023, then slipped by 15.41% to $3.6 million in 2024, then surged by 954.98% to $38.2 million in 2025, then soared by 117.06% to $83.0 million in 2026.
• Business Quant data shows SUPN's Other Accumulated Expenses at $83.0 million in Q1 2026, $38.2 million in Q4 2025, and $26.3 million in Q3 2025.